Companies ›Healthcare ›CMP.AX

CMP.AX — ASX Advanced Medical Equipment & Technology

Compumedics Ltd

A$0,24

Open in Charts → Attach watcher ⌖

— —

AUD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

2026-11-09

Ex-dividend

—

TR 1Y

—

About

Compumedics Ltd is a healthcare company specializing in advanced medical equipment and technology, primarily generating revenue through the development, manufacturing, and sale of medical devices and related services.

Business. Compumedics Ltd (CMP.AX) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of specialized medical devices. Compumedics is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

Generated · model-assisted

Sell-side consensus

BUY1 analysts

1 buy0 hold0 sell

Avg 12m price target0,80

Analyst recommendations

1 analysts · consensus Buy

Buy1

Hold0

Sell0

12-month price target

0,80

Consensus of sell-side coverage.

Upcoming events

EarningsFY 2026 earnings (expected)2026-11-09 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

1 analysts · indicative

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning CMP.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to CMP.AX. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsFY 2026 earnings (expected)2026-11-09 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR
Congressional trades
CongressJosh Gottheimer — Compass Minerals Intl Inc2021-11-16 · Democrat · NJ · Sale · $1,001 - $15,000

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Compumedics Ltd (CMP.AX) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of specialized medical devices. Compumedics is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

AI synthesis

GENERATED

Compumedics has a basic and diluted share count of 199,761,754, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

Profitability and return metrics are not available in the current valuation snapshot, making it difficult to compare Compumedics' performance against industry benchmarks or cohort medians. Analysts have not provided a clear outlook on the company's profitability or returns.

The company's revenue concentration and geographic exposure are not disclosed in the available data, limiting the ability to assess the risk associated with its segments or regions. Without this information, it is challenging to determine the diversification of its revenue streams.

Growth trajectory is also unclear, as no numeric deltas or revenue history are provided in the outlook. Analysts have issued a mean recommendation of 2.00, indicating a neutral stance, with a single "buy" rating and no "strong buy" or "hold" ratings.

Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, but the absence of detailed financial data limits the ability to evaluate potential dilution sources.

Recent events and filings do not provide additional insight into the company's operations or strategic direction. No recent transcripts or filings are available to inform the current analysis.

Key takeaways

Compumedics operates in the advanced medical equipment and technology industry with a high classification confidence.
The company has no immediate dilution pressure, as basic and diluted shares are equal.
Analysts have issued a neutral recommendation with a mean score of 2.00 and a single "buy" rating.
Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
Revenue concentration and geographic exposure are not disclosed, limiting the understanding of the company's diversification.
Growth trajectory and profitability metrics are not available, making it difficult to assess the company's future performance.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Annual

ANNUALFiled 2023-08-30

FY 2023 · Full-year highlights

Revenue A$42.4M, +12,3% YoY; Operating income −417,2% YoY.

RevenueA$42.4M+12,3 % YoY

Operating income-A$6.1M−417,2 % YoY

Net income-A$6.1M−551,1 % YoY

Free cash flow-A$9.5M−2 198,8 % YoY

EPS—

Operating cash flowA$49.0k−98,5 % YoY

Financials

Income statement

RevenueA$42.4M

Gross profitA$21.6M

Operating income-A$6.1M

Net income-A$6.1M

Margins

Gross margin50.9%

Operating margin-14.4%

Net margin-14.4%

FCF margin-22.4%

Balance sheet

Total assetsA$41.2M

Total liabilitiesA$22.9M

Total equityA$18.3M

Cash & equivalents—

Long-term debtA$9.5M

Cash flow

Operating cash flowA$49.0k

CapEx-A$4.4M

Free cash flow-A$9.5M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue A$42.4M, +12,3% YoY
▍Operating income −417,2% YoY
▍Net income −551,1% YoY
▍Free cash flow −2 198,8% YoY
▍Net margin -14.4%

Valuation FY

Market price

A$0,24

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships39 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries39

EX21:1156c7ad6d64EX21:1156c7ad6d64Subsidiarie97%

EX21:1ce29aea1fdeEX21:1ce29aea1fdeSubsidiarie97%

EX21:264267410026EX21:264267410026Subsidiarie97%

EX21:2b38e69a2995EX21:2b38e69a2995Subsidiarie97%

EX21:2c48705795b9EX21:2c48705795b9Subsidiarie97%

EX21:2f2a10948e9dEX21:2f2a10948e9dSubsidiarie97%

EX21:35eb28fc3e76EX21:35eb28fc3e76Subsidiarie97%

EX21:3c8c3aa892f3EX21:3c8c3aa892f3Subsidiarie97%

EX21:44b86477a309EX21:44b86477a309Subsidiarie97%

EX21:4b4e8644fec5EX21:4b4e8644fec5Subsidiarie97%

EX21:4d882a97a451EX21:4d882a97a451Subsidiarie97%

EX21:4e6c3dd06f92EX21:4e6c3dd06f92Subsidiarie97%

EX21:5e2f872092cfEX21:5e2f872092cfSubsidiarie97%

EX21:6083b176a3e3EX21:6083b176a3e3Subsidiarie97%

EX21:654c6580ef36EX21:654c6580ef36Subsidiarie97%

EX21:6b255cbf485fEX21:6b255cbf485fSubsidiarie97%

EX21:76c0d2565af8EX21:76c0d2565af8Subsidiarie97%

EX21:7e3a12968305EX21:7e3a12968305Subsidiarie97%

EX21:86c7ea24e6fbEX21:86c7ea24e6fbSubsidiarie97%

EX21:92897678d304EX21:92897678d304Subsidiarie97%

EX21:99dc4349041bEX21:99dc4349041bSubsidiarie97%

EX21:9ccd8b867b4fEX21:9ccd8b867b4fSubsidiarie97%

EX21:9d6ef4f0952dEX21:9d6ef4f0952dSubsidiarie97%

EX21:9dca2ca71cd1EX21:9dca2ca71cd1Subsidiarie97%

EX21:a205b3307690EX21:a205b3307690Subsidiarie97%

EX21:a6fffe7286bfEX21:a6fffe7286bfSubsidiarie97%

EX21:aa7241b82308EX21:aa7241b82308Subsidiarie97%

EX21:c2e785f120c2EX21:c2e785f120c2Subsidiarie97%

EX21:c779934ffa42EX21:c779934ffa42Subsidiarie97%

EX21:c94cea04207aEX21:c94cea04207aSubsidiarie97%

EX21:d3aa52c61146EX21:d3aa52c61146Subsidiarie97%

EX21:db97f305dfcaEX21:db97f305dfcaSubsidiarie97%

EX21:dcc6af9e2a6eEX21:dcc6af9e2a6eSubsidiarie97%

EX21:e286670a57d3EX21:e286670a57d3Subsidiarie97%

EX21:f1148b28bb81EX21:f1148b28bb81Subsidiarie97%

EX21:f6fb2c8b3f40EX21:f6fb2c8b3f40Subsidiarie97%

EX21:faa001a41c2bEX21:faa001a41c2bSubsidiarie97%

EX21:fc3a5dbe4772EX21:fc3a5dbe4772Subsidiarie97%

EX21:fd9598a1bb03EX21:fd9598a1bb03Subsidiarie97%

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,01
Revenue	—no estimate	—no estimate	71,4M AUD
Operating income	—no estimate	—no estimate	4,8M AUD

Full-year consensus mean (period as reported by source) · consensus in AUD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Corporate eventM&A horizon

M&A probabilityconf 3 %

Probability

3 %

Base rate

3 %

Band

—

180-day horizon · target 2027-01-18 · 1,0× base rate

No acquirer candidates identified by the signal model.

Probabilistic model output — not investment advice. · generated 2026-07-22

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy0

Buy1

Hold0

Sell0

Strong sell0

12-month price targetA$0,80 · Median A$0,80

Low A$0,80High A$0,80

Operating income · consensus4,8M AUD

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

LowA$0,80

MeanA$0,80

MedianA$0,80

HighA$0,80

SpotA$0,24

+226.5 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

M&A probabilityconf —

Probability

3 %

Base rate

3 %

Band

Low

180-day horizon · target 2027-01-18 · 1,0× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 81 385 sh13 exercises · 12 grants14 insiders

Ward AshleyChief Accounting Officer · Restricted Stock Unit → Common StockDisposed 8 333exercise · 2026-07-28
Nichols Benjamin S.Chief Commercial Officer · Restricted Stock Unit → Common StockDisposed 2 542exercise · 2026-06-24
Nichols Benjamin S.Chief Commercial Officer · Restricted Stock Unit → Common StockDisposed 685exercise · 2026-05-18
Nichols Benjamin S.Chief Commercial Officer · Restricted Stock Unit → Common StockDisposed 737exercise · 2026-05-13
DEALY RICHARD PDirector · Restricted Stock Unit → Common StockDisposed 11 905exercise · 2026-03-05
Reece Joseph EDirector · Deferred Stock Units → Common StockAcquired 9 434grant · 2026-03-05
DEALY RICHARD PDirector · Restricted Stock Unit → Common StockAcquired 5 032grant · 2026-03-05
WALKER LORI ADirector · Restricted Stock Unit → Common StockDisposed 11 905exercise · 2026-03-05
Reece Joseph EDirector · Deferred Stock Units → Common StockDisposed 22 322exercise · 2026-03-05
Ball Russell DavidDirector · Restricted Stock Unit → Common StockAcquired 5 032grant · 2026-03-05
Safran DavidDirector · Restricted Stock Unit → Common StockAcquired 5 032grant · 2026-03-05
Roberts Mark LawrenceDirector · Restricted Stock Unit → Common StockAcquired 5 032grant · 2026-03-05
Merle Denise MDirector · Restricted Stock Unit → Common StockAcquired 5 032grant · 2026-03-05
Joyce Gareth TDirector · Restricted Stock Unit → Common StockDisposed 11 905exercise · 2026-03-05
Joyce Gareth TDirector · Restricted Stock Unit → Common StockAcquired 5 032grant · 2026-03-05
Miller Melissa MDirector · Restricted Stock Unit → Common StockDisposed 11 905exercise · 2026-03-05
Miller Melissa MDirector · Restricted Stock Unit → Common StockAcquired 5 032grant · 2026-03-05
Merrin Patrick JamesChief Operations Officer · Restricted Stock Unit → Common StockDisposed 7 478exercise · 2026-03-03
Merrin Patrick JamesChief Operations Officer · Restricted Stock Unit → Common StockDisposed 11 047exercise · 2026-03-03
Fjellman PeterChief Financial Officer · Restricted Stock Unit → Common StockDisposed 8 321exercise · 2026-01-28
DOWLING EDWARD CDirector, President and CEO · Restricted Stock Unit → Common StockDisposed 22 350exercise · 2026-01-18
Ball Russell DavidDirector · Restricted Stock Unit → Common StockAcquired 1 348grant · 2025-12-18
Safran DavidDirector · Restricted Stock Unit → Common StockAcquired 1 348grant · 2025-12-18
Roberts Mark LawrenceDirector · Restricted Stock Unit → Common StockAcquired 1 348grant · 2025-12-18
Merle Denise MDirector · Restricted Stock Unit → Common StockAcquired 1 348grant · 2025-12-18

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic

Source documents

Compumedics Ltd Market data — financials · 2026-05-27
Compumedics Ltd Market data — analyst estimates · 2026-05-27

Ownership & reference

Insider activity

Mixed / flat0 buys · 0 sellsnet $014 insiders · last 365d

Ward AshleyChief Accounting Officer · Common StockOther 2 443 @ $29,69$73K · 2026-07-28
Ward AshleyChief Accounting Officer · Common StockOther 8 333 · 2026-07-28
Reece Joseph EDirector · Common StockOther 1 205 · 2026-06-30
Safran DavidDirector · Common StockOther 804 · 2026-06-30
DEALY RICHARD PDirector · Common StockOther 944 · 2026-06-30
Nichols Benjamin S.Chief Commercial Officer · Common StockOther 2 542 · 2026-06-24
Nichols Benjamin S.Chief Commercial Officer · Common StockOther 747 @ $28,66$21K · 2026-06-24
Nichols Benjamin S.Chief Commercial Officer · Common StockOther 685 · 2026-05-18
Nichols Benjamin S.Chief Commercial Officer · Common StockOther 195 @ $28,97$6K · 2026-05-18
Nichols Benjamin S.Chief Commercial Officer · Common StockOther 247 @ $30,21$7K · 2026-05-13
Nichols Benjamin S.Chief Commercial Officer · Common StockOther 737 · 2026-05-13
DEALY RICHARD PDirector · Common StockOther 1 259 · 2026-03-31
Safran DavidDirector · Common StockOther 1 071 · 2026-03-31
Reece Joseph EDirector · Common StockOther 1 816 · 2026-03-31
Miller Melissa MDirector · Common StockOther 11 905 · 2026-03-05
Reece Joseph EDirector · Common StockOther 22 322 · 2026-03-05
Joyce Gareth TDirector · Common StockOther 11 905 · 2026-03-05
WALKER LORI ADirector · Common StockOther 11 905 · 2026-03-05
DEALY RICHARD PDirector · Common StockOther 11 905 · 2026-03-05
Merrin Patrick JamesChief Operations Officer · Common StockOther 5 003 @ $24,68$123K · 2026-03-03
Merrin Patrick JamesChief Operations Officer · Common StockOther 18 525 · 2026-03-03
Fjellman PeterChief Financial Officer · Common StockOther 8 321 · 2026-01-28
Fjellman PeterChief Financial Officer · Common StockOther 2 720 @ $25,90$70K · 2026-01-28
DOWLING EDWARD CDirector, President and CEO · Common StockOther 6 878 @ $23,29$160K · 2026-01-18
DOWLING EDWARD CDirector, President and CEO · Common StockOther 22 350 · 2026-01-18

Short positioning

1.3Mshares short+5.4% vs prior

3.72days to cover

56.6%short of daily vol

363fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

CMP.AXCanonical

ASX · AUD

Intel & risk

PredictorM&A prob3 %Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Current ratio (FY 2025-12-31): 2.59xDerived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -1.0%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -9.3%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -11.3%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 2.0%Derived (calculated)
Current assets (annual): USD 632.2MSEC XBRL filing
Total assets (annual): USD 1.53BSEC XBRL filing
Cash & equivalents (annual): USD 46.7MSEC XBRL filing
Current liabilities (annual): USD 243.7MSEC XBRL filing
Shareholders' equity (annual): USD 260.5MSEC XBRL filing
Long-term debt (annual): USD 883.6MSEC XBRL filing
Operating income (YoY) (2025-09-30 vs 2024-09-30): 121.7%Derived (calculated)
Operating cash flow (YoY) (2025-09-30 vs 2024-09-30): 1,272.9%Derived (calculated)
Net margin (FY 2025-09-30): -6.4%Derived (calculated)
Gross margin (FY 2025-09-30): 15.3%Derived (calculated)
Revenue (YoY) (2025-09-30 vs 2024-09-30): 11.3%Derived (calculated)
Net income (YoY) (2025-09-30 vs 2024-09-30): 61.3%Derived (calculated)
Gross profit (YoY) (2025-09-30 vs 2024-09-30): -2.2%Derived (calculated)
Revenue (annual): USD 1.24BSEC XBRL filing
Pre-tax income (annual): USD -53.7MSEC XBRL filing
Net income (annual): USD -79.8MSEC XBRL filing
Operating cash flow (annual): USD 197.7MSEC XBRL filing
Operating income (annual): USD 25.3MSEC XBRL filing
Gross profit (annual): USD 190.7MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-11-09EVENTUpcomingFY 2026 earnings (expected) estimated date

2026-07-28INSIDERWard Ashley transacted 2.4k sh Common Stock — Chief Accounting Officer ~$73k

2026-07-28INSIDERWard Ashley transacted 8.3k sh Common Stock — Chief Accounting Officer

2026-07-28INSIDERWard Ashley disposed of 8.3k sh Restricted Stock Unit — Chief Accounting Officer

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-30INSIDERReece Joseph E transacted 1.2k sh — Director

2026-06-30INSIDERDEALY RICHARD P transacted 944 sh — Director

2026-06-30INSIDERSafran David transacted 804 sh Common Stock — Director

2026-06-24 00:00 UTCINSIDER3 insider transactions — 2026-06 1 derivative

2026-06-24INSIDERNichols Benjamin S. transacted 747 sh Common Stock — Chief Commercial Officer ~$21k

2026-06-24INSIDERNichols Benjamin S. transacted 2.5k sh Common Stock — Chief Commercial Officer

2026-06-24INSIDERNichols Benjamin S. disposed of 2.5k sh Restricted Stock Unit — Chief Commercial Officer

2026-06-23 03:11 UTCHOLDERInstitutional holding changed

2026-06-23 03:11 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-21 02:57 UTCHOLDERInstitutional holding changed

2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-05-18 00:00 UTCINSIDER6 insider transactions — 2026-05 2 derivative

2026-05-18INSIDERNichols Benjamin S. transacted 685 sh Common Stock — Chief Commercial Officer

2026-05-18INSIDERNichols Benjamin S. transacted 195 sh Common Stock — Chief Commercial Officer ~$6k

2026-05-18INSIDERNichols Benjamin S. disposed of 685 sh Restricted Stock Unit — Chief Commercial Officer

2026-05-13INSIDERNichols Benjamin S. transacted 247 sh Common Stock — Chief Commercial Officer ~$7k

2026-05-13INSIDERNichols Benjamin S. transacted 737 sh Common Stock — Chief Commercial Officer

2026-05-13INSIDERNichols Benjamin S. disposed of 737 sh Restricted Stock Unit — Chief Commercial Officer

2026-05-07FILING10-Q filing →

2026-05-06FILING8-K filing →

2026-03-31 00:00 UTCINSIDER25 insider transactions — 2026-03 · net sell $123k 15 derivative

2026-03-31INSIDERDEALY RICHARD P transacted 1.3k sh — Director

2026-03-31INSIDERSafran David transacted 1.1k sh Common Stock — Director

2026-03-31INSIDERReece Joseph E transacted 1.8k sh — Director

2026-03-24FILING8-K filing →

2026-03-10FILING8-K filing →

2026-03-05INSIDERMiller Melissa M transacted 11.9k sh — Director

2026-03-05INSIDERReece Joseph E transacted 22.3k sh — Director

2026-03-05INSIDERJoyce Gareth T transacted 11.9k sh — Director

2026-03-05INSIDERWALKER LORI A transacted 11.9k sh — Director

2026-03-05INSIDERDEALY RICHARD P transacted 11.9k sh — Director

2026-03-05INSIDERDEALY RICHARD P disposed of 11.9k sh Restricted Stock Unit — Director

2026-03-05INSIDERSafran David acquired 5.0k sh Restricted Stock Unit — Director

2026-03-05INSIDERRoberts Mark Lawrence acquired 5.0k sh Restricted Stock Unit — Director

Showing the 40 most recent of 68 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread